Repurposed Therapeutics, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Tampa FL United States (2014)
Status: No NME R&D (2014)

Organization Overview

First Clinical Trial
2014
NCT02155309
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Repurposed Therapeutics | Repurposed Therapeutics, Inc. | Repurposed Therapuetics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

scopolamine (transderm scop) (11 trials)

Drugs in Phase 2 Trials (1)

promethazine hydrochloride (phenergan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Depressive Disorder (Phase 1)

Depressive Disorder, Major (Phase 1)

Motion Sickness (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial APIs: 2